MX2019002115A - Terapias de combinacion para el tratamiento de carcinoma hepatocelular. - Google Patents
Terapias de combinacion para el tratamiento de carcinoma hepatocelular.Info
- Publication number
- MX2019002115A MX2019002115A MX2019002115A MX2019002115A MX2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A
- Authority
- MX
- Mexico
- Prior art keywords
- hepatocellular carcinoma
- treatment
- combination therapies
- inhibitor
- combination
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 title abstract 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title abstract 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 229940125408 FGFR4 inhibitor Drugs 0.000 abstract 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporciona en la presente una terapia de combinación útil para el tratamiento de carcinoma hepatocelular y/o colangiocarcinoma intrahepático. La combinación comprende un inhibidor de FGFR4 y un inhibidor de CDK 4/6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662378455P | 2016-08-23 | 2016-08-23 | |
PCT/US2017/048183 WO2018039324A1 (en) | 2016-08-23 | 2017-08-23 | Combination therapies for the treatment of hepatocellular carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019002115A true MX2019002115A (es) | 2019-07-08 |
Family
ID=59772765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019002115A MX2019002115A (es) | 2016-08-23 | 2017-08-23 | Terapias de combinacion para el tratamiento de carcinoma hepatocelular. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190175598A1 (es) |
EP (1) | EP3503923B1 (es) |
JP (1) | JP7190425B2 (es) |
KR (1) | KR102466192B1 (es) |
CN (1) | CN109803684B (es) |
AU (1) | AU2017315357B2 (es) |
BR (1) | BR112019003722A2 (es) |
CA (1) | CA3034875A1 (es) |
ES (1) | ES2966469T3 (es) |
IL (1) | IL264950B2 (es) |
MX (1) | MX2019002115A (es) |
RU (1) | RU2769251C2 (es) |
SG (1) | SG11201901472TA (es) |
WO (1) | WO2018039324A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2020123665A (ru) | 2018-01-08 | 2022-02-10 | Г1 Терапьютикс, Инк. | Преимущественные режимы дозирования g1т38 |
US11911383B2 (en) | 2018-05-14 | 2024-02-27 | Pfizer Inc. | Oral solution formulation |
TW202128173A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
JP2023533903A (ja) * | 2020-05-15 | 2023-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Fgfr4阻害剤の経口製剤によるがんの治療方法 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
DE19959546A1 (de) | 1999-12-09 | 2001-06-21 | Rhone Poulenc Rorer Gmbh | Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen |
PT1252155E (pt) | 2000-01-18 | 2005-04-29 | Aventis Pharma Inc | Solvato de etanol de (-)-cis-2-(2-clorofenil)-5,7-di-hidroxi-8-[4r-(3s-hidroxi-1-metil)piperidinil]-4h-1-bezopiran-4-ona |
WO2001053293A1 (en) | 2000-01-18 | 2001-07-26 | Aventis Pharmaceuticals Inc. | Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one |
AU2001287157A1 (en) | 2000-09-12 | 2002-03-26 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
ATE314370T1 (de) | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
US20080161355A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
JP5475235B2 (ja) | 2005-01-21 | 2014-04-16 | アステックス・セラピューティクス・リミテッド | 医薬化合物 |
KR101345002B1 (ko) | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
JP2008255008A (ja) | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
US20110159111A1 (en) | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
US20090263398A1 (en) | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
US20100021420A1 (en) | 2006-07-14 | 2010-01-28 | Astex Therapeutics Limited | Combinations of pyrazole derivatives for the inhibition of cdks and gsk's |
JP2009544602A (ja) | 2006-07-21 | 2009-12-17 | アステックス・セラピューティクス・リミテッド | サイクリン依存性キナーゼ阻害剤の医学的使用 |
EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
EP2282995B1 (en) * | 2008-05-23 | 2015-08-26 | Novartis AG | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
PL2331547T3 (pl) | 2008-08-22 | 2015-01-30 | Novartis Ag | Związki pirolopirymidynowe jako inhibitory CDK |
PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
MX2012011912A (es) * | 2010-04-13 | 2012-11-16 | Novartis Ag | Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer. |
JP5923509B2 (ja) | 2010-10-25 | 2016-05-24 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | Cdk阻害剤 |
US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
KR20160035613A (ko) * | 2011-03-23 | 2016-03-31 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
EP2726076B1 (en) * | 2011-07-01 | 2016-10-12 | Novartis AG | Combination therapy |
AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
WO2014097125A1 (en) * | 2012-12-20 | 2014-06-26 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
US9527857B2 (en) | 2013-03-15 | 2016-12-27 | GI Therapeutics, Inc. | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
PT3033086T (pt) * | 2013-08-14 | 2021-12-15 | Novartis Ag | Terapia de combinação para o tratamento de cancro |
TWI597268B (zh) * | 2013-10-18 | 2017-09-01 | 衛材R&D企管股份有限公司 | 纖維母細胞受體4(fgfr4)抑制劑 |
WO2016025650A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
CN104529904B (zh) | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
WO2016126889A1 (en) | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
ES2864712T3 (es) * | 2015-04-14 | 2021-10-14 | Eisai R&D Man Co Ltd | Compuesto inhibidor de FGFR4 cristalino y usos del mismo |
-
2017
- 2017-08-23 CN CN201780062334.3A patent/CN109803684B/zh active Active
- 2017-08-23 SG SG11201901472TA patent/SG11201901472TA/en unknown
- 2017-08-23 WO PCT/US2017/048183 patent/WO2018039324A1/en unknown
- 2017-08-23 RU RU2019108259A patent/RU2769251C2/ru active
- 2017-08-23 IL IL264950A patent/IL264950B2/en unknown
- 2017-08-23 US US16/324,643 patent/US20190175598A1/en not_active Abandoned
- 2017-08-23 BR BR112019003722A patent/BR112019003722A2/pt unknown
- 2017-08-23 EP EP17761701.6A patent/EP3503923B1/en active Active
- 2017-08-23 ES ES17761701T patent/ES2966469T3/es active Active
- 2017-08-23 KR KR1020197008327A patent/KR102466192B1/ko active IP Right Grant
- 2017-08-23 CA CA3034875A patent/CA3034875A1/en active Pending
- 2017-08-23 AU AU2017315357A patent/AU2017315357B2/en active Active
- 2017-08-23 JP JP2019511500A patent/JP7190425B2/ja active Active
- 2017-08-23 MX MX2019002115A patent/MX2019002115A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20190040996A (ko) | 2019-04-19 |
CA3034875A1 (en) | 2018-03-01 |
AU2017315357A1 (en) | 2019-02-28 |
RU2019108259A (ru) | 2020-09-25 |
IL264950A (en) | 2019-05-30 |
RU2019108259A3 (es) | 2020-11-24 |
JP2019528302A (ja) | 2019-10-10 |
KR102466192B1 (ko) | 2022-11-14 |
CN109803684B (zh) | 2022-08-23 |
WO2018039324A1 (en) | 2018-03-01 |
BR112019003722A2 (pt) | 2019-05-28 |
CN109803684A (zh) | 2019-05-24 |
EP3503923B1 (en) | 2023-10-04 |
JP7190425B2 (ja) | 2022-12-15 |
AU2017315357B2 (en) | 2022-12-01 |
ES2966469T3 (es) | 2024-04-22 |
EP3503923A1 (en) | 2019-07-03 |
US20190175598A1 (en) | 2019-06-13 |
RU2769251C2 (ru) | 2022-03-29 |
IL264950B1 (en) | 2023-09-01 |
IL264950B2 (en) | 2024-01-01 |
SG11201901472TA (en) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003939A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. | |
SG11202001728YA (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
MX2022008868A (es) | Tratamiento del cancer con tg02. | |
EP4302835A3 (en) | Methods of treating ovarian cancer | |
SG10201804931QA (en) | Anti-cll-1 antibodies and immunoconjugates | |
MX2019002115A (es) | Terapias de combinacion para el tratamiento de carcinoma hepatocelular. | |
MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
MX2021011946A (es) | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
MX2018006152A (es) | Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico. | |
PH12019501373A1 (en) | Methods of treating cochlears synaptopathy | |
IL283948A (en) | Methods for treating depression | |
MX2018010709A (es) | Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control. | |
MX2018011875A (es) | Reprogramacion cardiaca directa mejorada. | |
MX2015010077A (es) | Terapia de combinacion para el tratamiento de neumonia nosocomial. | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
EA201890728A2 (ru) | Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами | |
MX2019010981A (es) | Terapias de combinacion para el tratamiento de cancer de mama. | |
PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
GB201721793D0 (en) | Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza | |
EP3426256A4 (en) | METHOD OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND DISEASES ASSOCIATED WITH SGLT-2 INHIBITOR | |
WO2016046414A3 (en) | Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse | |
MX2020007375A (es) | Terapias de combinacion para el tratamiento de carcinoma hepatocelular. | |
MX2020011912A (es) | Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc). | |
PH12018501213A1 (en) | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1h-pyrazol-3-ylamino)pyrazine-2-carbonitrile (s)-lactate monohydrate |